Life Sciences Academy | Unlocking Health Data for Cross-Border AI Innovation: Navigating Privacy Compliance in the EU and UK

Our case study explores a health care / life sciences organisation seeking to leverage existing health data to develop an AI technology.  The health data was collected years ago under broad consent for "future research." Now it needs to flow across borders and be further processed for AI development.

Sounds familiar?

Join three of Osborne Clarke's international health data experts as they dissect this real-world scenario and show you how to navigate the legal maze of cross-border health data innovation under EU and UK privacy law.

What You'll Learn:

• Broad consent and legal basis: When is consent from clinical trials sufficient for commercial AI development, and how do national approaches differ across jurisdictions?
• Pseudonymisation vs anonymisation: What is the impact of recent CJEU rulings on data privacy for these types of cross-border health research projects? Can this decision reduce the compliance burden in the context of international AI research projects?
• Emerging regulation: Do the EHDS or the Digital Omnibus provide permission grounds to re-use health data for AI innovation projects?
• Cross-border data transfers and multi-party responsibilities: How can you overcome the practical challenges of moving health data internationally between several stakeholders?